ペンシルベニアにおける血友病Bの臨床試験
ペンシルベニア内の拠点で、血友病Bに関する6件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
被験者募集中第3相
18歳以上 · 男性 · 2026/10/02更新 · NCT05568719A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Children's Hospital of Philadelphia (CHOP), Philadelphia
被験者募集中第1/2相
2歳以上 · 男性 · 2026/09/11更新 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06003387ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Hospital of Philadelphia, Philadelphia
- Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania, Philadelphia
- St. Christopher's Hospital for Children, Philadelphia
- 他1件
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/17更新 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Penn State Milton S Hershey Medical Center Pediatrics, Hershey
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia
被験者募集中第1相健康なボランティア歓迎
18歳〜60歳 · 全性別 · 2026/07/02更新 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- The Feinstein Institutes for Medical Research, Philadelphia
被験者募集中第3相
1歳〜74歳 · 男性 · 2026/07/01更新 · NCT05145127ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。